Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Lack of cortistatin drives neuroimmune and vascular dysfunction in brain ischemia.

Journal of biomedical science·2026

Same author

Correlation Between Quantitative Pupillometry and Other Markers for Neuroprognostication of Comatose Patients After Cardiac Arrest: A Bicentric Study.

Critical care medicine·2026

Same author

Status Epilepticus Is Detected Earlier than Seizures on cEEG in Critically Ill Adults.

Neurocritical care·2026

Same author

Effects of midazolam and propofol on EEG detection of epileptiform activity in patients with altered consciousness.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2026

Same author

Monitoring carotid arterial stiffness using non-contrast-enhanced 4D MR angiography.

European radiology experimental·2026

Same author

Mood and Age Predict Cognitive Complaints in Memory Clinic Patients: A Machine-Learning and Linear Modeling Approach.

European journal of neurology·2026

Same journal

Revue medicale suisse·2026

Same journal

Revue medicale suisse·2026

Same journal

Revue medicale suisse·2026

Same journal

Revue medicale suisse·2026

Same journal

Revue medicale suisse·2026

Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Feb 15, 2026

Recording Horizontal Saccade Performances Accurately in Neurological Patients Using Electro-oculogram

Recording Horizontal Saccade Performances Accurately in Neurological Patients Using Electro-oculogram

Published on: March 13, 2018

[Neurology].

Isabelle Chopard¹, David Benninger¹, Jean-François Demonet¹

¹Service de neurologie, Département des neurosciences cliniques, CHUV, 1011 Lausanne.

Revue Medicale Suisse

|January 17, 2018

Summary

This summary is machine-generated.

New therapeutic strategies are emerging for neurological disorders. Ocrelizumab for multiple sclerosis, eculizumab for myasthenia gravis, and patisiran for amyloidosis show promise. Non-pharmacological migraine treatments and revised dementia criteria are also noted.

More Related Videos

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Lipidomics and Transcriptomics in Neurological Diseases

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

Related Experiment Videos

Last Updated: Feb 15, 2026

Recording Horizontal Saccade Performances Accurately in Neurological Patients Using Electro-oculogram

Recording Horizontal Saccade Performances Accurately in Neurological Patients Using Electro-oculogram

Published on: March 13, 2018

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Lipidomics and Transcriptomics in Neurological Diseases

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

Area of Science:

Neurology
Immunology
Genetics
Pharmacology

Background:

Advances in treating neurological conditions are rapidly evolving.
Targeted therapies and revised diagnostic criteria are improving patient outcomes.
Multiple sclerosis, myasthenia gravis, and amyloidosis represent significant challenges in neuro-immunology and genetics.

Purpose of the Study:

To review recent advancements in the treatment of multiple sclerosis, myasthenia gravis, and transthyretin familial amyloidosis.
To highlight emerging non-pharmacological approaches for headache and migraine management.
To note revisions in diagnostic criteria for Lewy body dementia and the safety of generic lamotrigine.

Main Methods:

Review of approved therapies including monoclonal antibodies and gene therapy.
Discussion of non-pharmacological interventions for migraines.
Summary of updated diagnostic criteria for Lewy body dementia.
Analysis of safety data for generic lamotrigine.

Main Results:

Ocrelizumab (anti-CD20) is approved for multiple sclerosis.
Eculizumab (Soliris) is approved for severe generalized myasthenia gravis.
Patisiran gene therapy shows positive results in transthyretin familial amyloidosis.
Non-pharmacological migraine treatments show promise.
Revised criteria for Lewy body dementia are available.
Generic lamotrigine use is safe regarding seizures and adverse effects.

Conclusions:

Significant progress has been made in targeted therapies for neurological and neuromuscular disorders.
Diverse treatment modalities, from immunotherapy to gene therapy and non-pharmacological approaches, are expanding therapeutic options.
Updated diagnostic criteria and safety profiles of generic medications contribute to better patient management.